A phase II study of nivolumab cabiralizumab and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer

Brief description of study

If you have been diagnosed with pancreatic cancer, you may qualify for this Phase II study. The main goal of this study is to determine if cabiralizumab and nivolumab, as well as radiotherapy (radiation therapy) is safe and tolerable while treating your cancer, as well as to determine the effects the study drugs and therapy will have on your cancer treatment.


Clinical Study Identifier: s17-01430
ClinicalTrials.gov Identifier: NCT03599362
Principal Investigator: Deirdre J Cohen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.